United Therapeutics Corporation (UTHR) FY2026 YTD Q2 P&L / Income Statement

United Therapeutics Corporation (UTHR) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Product and service. Revenue and costs use their disclosed categories.

Total revenues

1,564,800,000 US dollars

Cost of sales

232,900,000 US dollars

Gross profit (calculated)

1,331,900,000 US dollars

Operating expenses (calculated)

675,300,000 US dollars

Operating income

656,600,000 US dollars

Total other income, net

34,400,000 US dollars

Income before income taxes

691,000,000 US dollars

Income tax expense

83,100,000 US dollars

Net income

607,900,000 US dollars

Remodulin revenue

252,900,000 US dollars

Orenitram revenue

261,300,000 US dollars

Unituxin revenue

118,800,000 US dollars

Adcirca revenue

9,600,000 US dollars

Other revenue

12,100,000 US dollars

Tyvaso DPI revenue

656,900,000 US dollars

Nebulized Tyvaso revenue

253,200,000 US dollars

Remodulin cost of revenue

33,500,000 US dollars

Orenitram cost of revenue

13,500,000 US dollars

Unituxin cost of revenue

7,000,000 US dollars

Adcirca cost of revenue

4,000,000 US dollars

Other cost of revenue

23,100,000 US dollars

Tyvaso DPI cost of revenue

134,300,000 US dollars

Nebulized Tyvaso cost of revenue

17,500,000 US dollars

Research and development

284,500,000 US dollars

Selling, general, and administrative

390,800,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.